Pournajaf S, Dargahi L, Javan M, Pourgholami M
Front Pharmacol. 2022; 13:807639.
PMID: 35250559
PMC: 8889014.
DOI: 10.3389/fphar.2022.807639.
Gomez-Brouchet A, Illac C, Ledoux A, Fortin P, De Barros S, Vabre C
Cancers (Basel). 2022; 14(3).
PMID: 35158767
PMC: 8833796.
DOI: 10.3390/cancers14030499.
Suzuki S, Ogawa M, Miyazaki M, Ota K, Kazama H, Hirota A
Oncol Rep. 2021; 47(2).
PMID: 34958115
PMC: 8759104.
DOI: 10.3892/or.2021.8251.
Moritz E, Jedlitschky G, Negnal J, Tzvetkov M, Daum G, Dorr M
J Inflamm Res. 2021; 14:2883-2896.
PMID: 34234513
PMC: 8256099.
DOI: 10.2147/JIR.S302117.
Roy S, Mahapatra A, Mohammad T, Gupta P, Alajmi M, Hussain A
Pharmaceuticals (Basel). 2020; 13(6).
PMID: 32526899
PMC: 7346089.
DOI: 10.3390/ph13060118.
Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases.
Diarte-Anazco E, Mendez-Lara K, Perez A, Alonso N, Blanco-Vaca F, Julve J
Int J Mol Sci. 2019; 20(24).
PMID: 31842389
PMC: 6940915.
DOI: 10.3390/ijms20246273.
Approaches for probing and evaluating mammalian sphingolipid metabolism.
Snider J, Luberto C, Hannun Y
Anal Biochem. 2019; 575:70-86.
PMID: 30917945
PMC: 6498843.
DOI: 10.1016/j.ab.2019.03.014.
Field template-based design and biological evaluation of new sphingosine kinase 1 inhibitors.
Alshaker H, Srivats S, Monteil D, Wang Q, Low C, Pchejetski D
Breast Cancer Res Treat. 2018; 172(1):33-43.
PMID: 30043096
PMC: 6208908.
DOI: 10.1007/s10549-018-4900-1.
Essential Role of Sphingosine Kinase 2 in the Regulation of Cargo Contents in the Exosomes from K562 Cells.
Ibrahim Mohamed N, Okada T, Kajimoto T, Nakamura S
Kobe J Med Sci. 2018; 63(4):E123-E129.
PMID: 29955024
PMC: 6192818.
The differential effects of FTY720 on functional recovery and infarct size following myocardial ischaemia/reperfusion.
van Vuuren D, Marais E, Genade S, Lochner A
Cardiovasc J Afr. 2016; 27(6):375-386.
PMID: 27966000
PMC: 5408499.
DOI: 10.5830/CVJA-2016-039.
Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation.
McCracken A, McMonigle R, Tessier J, Fransson R, Perryman M, Chen B
Leukemia. 2016; 31(3):669-677.
PMID: 27573555
PMC: 5332311.
DOI: 10.1038/leu.2016.244.
The emerging role of FTY720 (Fingolimod) in cancer treatment.
White C, Alshaker H, Cooper C, Winkler M, Pchejetski D
Oncotarget. 2016; 7(17):23106-27.
PMID: 27036015
PMC: 5029614.
DOI: 10.18632/oncotarget.7145.
S1pping fire: Sphingosine-1-phosphate signaling as an emerging target in inflammatory bowel disease and colitis-associated cancer.
Degagne E, Saba J
Clin Exp Gastroenterol. 2014; 7:205-14.
PMID: 25061328
PMC: 4085325.
DOI: 10.2147/CEG.S43453.
The role of sphingosine kinase isoforms and receptors S1P1, S1P2, S1P3, and S1P5 in primary, secondary, and recurrent glioblastomas.
Quint K, Stiel N, Neureiter D, Schlicker H, Nimsky C, Ocker M
Tumour Biol. 2014; 35(9):8979-89.
PMID: 24903384
DOI: 10.1007/s13277-014-2172-x.
A review of ceramide analogs as potential anticancer agents.
Liu J, Beckman B, Foroozesh M
Future Med Chem. 2013; 5(12):1405-21.
PMID: 23919551
PMC: 4216473.
DOI: 10.4155/fmc.13.107.
Sphingolipids in cardiovascular and cerebrovascular systems: Pathological implications and potential therapeutic targets.
Kawabori M, Kacimi R, Karliner J, Yenari M
World J Cardiol. 2013; 5(4):75-86.
PMID: 23675553
PMC: 3653015.
DOI: 10.4330/wjc.v5.i4.75.
FTY720 postconditions isolated perfused heart by a mechanism independent of sphingosine kinase 2 and different from S1P or ischemic postconditioning.
Vessey D, Li L, Imhof I, Honbo N, Karliner J
Med Sci Monit Basic Res. 2013; 19:126-32.
PMID: 23567658
PMC: 3659128.
DOI: 10.12659/MSMBR.883877.
Sphingolipids: a potential molecular approach to treat allergic inflammation.
Sun W, Bonder C
J Allergy (Cairo). 2013; 2012:154174.
PMID: 23316248
PMC: 3536436.
DOI: 10.1155/2012/154174.
Sphingolipids: regulators of crosstalk between apoptosis and autophagy.
Young M, Kester M, Wang H
J Lipid Res. 2012; 54(1):5-19.
PMID: 23152582
PMC: 3520539.
DOI: 10.1194/jlr.R031278.
Sphingosine and FTY720 are potent inhibitors of the transient receptor potential melastatin 7 (TRPM7) channels.
Qin X, Yue Z, Sun B, Yang W, Xie J, Ni E
Br J Pharmacol. 2012; 168(6):1294-312.
PMID: 23145923
PMC: 3596637.
DOI: 10.1111/bph.12012.